Biological Response Modifiers in Cancer

Purabi Reang, MD; Madhur Gupta, MD; Kamlesh Kohli, MD


November 14, 2006


Epratuzumab (LL2) is a murine IgG2a antibody targeted against CD22 antigen (transferrin receptor). It is widely expressed during B-cell development and is present in most of NHL tumours[64] Juweid and colleagues[65] compared 131ILL2 with 90Y LL2 in patients with relapsed/refractory NHL. 90Y LL2 treatment was found to be more effective than 131I LL2, the objective tumor response being 29% and 15%, respectively, with these treatments.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.